Brief: Satsuma Pharmaceuticals Announces Enrollment Of First Patient In The Ascend™ Phase 3 Open-Label, Safety Trial Of Sts101
06/08/2020 21:26
Aug 6 (Reuters) - Satsuma Pharmaceuticals Inc STSA.O :
* SATSUMA PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST
PATIENT IN
THE ASCEND™ PHASE 3 OPEN-LABEL, SAFETY TRIAL OF STS101
* SATSUMA PHARMACEUTICALS INC - ASCEND RESULTS EXPECTED TO
SUPPORT
STS101 NDA FILING IN Q4 2021
Source text for Eikon: ID:nGNX8GtZCn
Further company coverage: STSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Satsuma Pharmaceuticals
See all newsBrief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Brief: Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
Satsuma Pharma soars on buyout deal from Japan's Shin Nippon